Deals channel feed – Endpoints News

Deals channel feed

JP Morgan splashes into the life sciences, tapping Stephen Squinto to run venture team with high-powered advisors

3 years ago

Thermo Fisher wagers on early cancer diagnostics in $2.6B cash deal for multiple myeloma test maker

3 years ago

Intrinsic wanted an IPO. Instead, it's a SPAC for the gut-brain microbiome biotech

3 years ago

J&J presses pause on a partner's PhI prostate cancer study, cutting off potential Erleada combo

3 years ago

In final pivot from cancer to rare disease, Agios offloads its share of Tibsovo royalties for $131M

3 years ago

Moderna nearing deal with US government to develop Ebola vaccines — report

3 years ago

A one-time pop singer with mega-money star connections hatches a $100M plan to invest in ‘contrarian’ biotech ideas

3 years ago

Using herpes virus vectors, Paul Peter Tak and Carl June team up to solve the CAR-T solid tumor challenge

3 years ago

CEPI teams up with Korean vaccine maker in $140M pact to scale up its nascent mRNA platform

3 years ago

Updated: In broad retreat, GSK's new R&D leader abandons NY-ESO plans, pulls plug on cell therapy 2.0 alliances after losing faith

3 years ago

Prelude to buyout? Astellas picks up Taysha stock, two gene therapy programs for $50M

3 years ago

In $23M deal, Syncona adds ex-Biogen partner and 20-year-old gene therapy outfit AGTC to portfolio

3 years ago

As top investor makes its play to grab lead drug, PhaseBio counters with Chapter 11, stalking-horse bid

3 years ago

Sumitomo clinches Myovant buyout after upping offer to $2.9B

3 years ago

Gilead presses forward with next-gen CAR-T, inking deal with small synthetic biology startup

3 years ago

Updated: With new $100M investment, a biotech with two approved drugs spins out its manufacturing business

3 years ago

Novartis signs landmark licensing deal to expand access to patented cancer drug

3 years ago

'Hook'ed on KRAS, Roche lines up licensing deal as it pursues Mirati and Amgen

3 years ago

Playboy, digital health, electric vehicles and now cancer drugs: A mountainous SPAC journey

3 years ago

AbbVie recruits a GPCR team in Oxford, buying out a fledgling biotech for $255M+

3 years ago

Takeda adds one more late-stage treatment to its growing roster of celiac drugs

3 years ago

Two public biotechs seek to merge, focusing on desmoid tumors. But Nasdaq is not guaranteed

3 years ago

Can a little startup equipped with an Eli Lilly castoff make it big with an oncology IPO? In 2022?

3 years ago

Updated: Zymeworks wanted a Big Pharma partner for its bispecific. Jazz Pharmaceuticals said OK

3 years ago

First page Previous page 47 48 495051 52 53 Next page Last page